On one hand, novel HER2 dual blockade strategies based on the combination of trastuzumab plus pertuzumab (humanized monoclonal antibodies) have entered the treatment landscape of BC both in metastatic, adjuvant and neoadjuvant settings6–8, and additional blockbuster drugs are under clinical development9,10. This evidence concerns the gene ERBB2 and breast cancer.